We are an AI-driven company with a unique ability to match drugs to indications and prosecute through clinical development. AI Therapeutics’ revolutionary approach to drug discovery and development has advanced three drugs into clinical trials.
AI Therapeutics was founded in 2013 as LAM Therapeutics with a mission to advance the clinical development of new therapies to treat Lymphangioleiomyomatosis (LAM) and other diseases. In 2018 we changed our name to AI Therapeutics. Working with a dedicated team of scientific, clinical, and drug development experts, AI Therapeutics is pioneering deep learning-based AI to outsmart cancer and rare diseases.
Total Funding: $98,000,000
Funding Stage: Series C
Business Stage: Scaling Up
Market: B2B
Company Size: 101 to 250
Founded: 2013
